Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China

Journal of Viral Hepatitis

Volumn 20, Issue 11, 2013, Pages 811-820

  Hou, J L ^a   Jia, J D ^b   Wei, L ^c   Zhao, W ^d   Wang, Y M ^e   Cheng, M ^f   Tang, X ^g   Tan, D M ^h   Ren, H ⁱ   Tang, H ^j   Cohen, D ^k   Llamoso, C ^k  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d SOUTHEAST UNIVERSITY   (China)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f GUIZHOU MEDICAL UNIVERSITY   (China)

^g Guangzhou Eighth People's Hospital   (China)

^h CENTRAL SOUTH UNIVERSITY   (China)

ⁱ CHONGQING MEDICAL UNIVERSITY   (China)

^j SICHUAN UNIVERSITY   (China)

^k BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

antiviral therapy; Asian; hepatitis B virus; nucleos(t)ide analogue; real life

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASCITES; CHINA; CHOLELITHIASIS; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATOBILIARY DISEASE; HUMAN; INFECTION; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84885442032     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12115     Document Type: Article

References (36)

1. World Health Organization. Hepatitis B [Fact sheet N°204. July 2012]. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
2. Liang X, Bi S, Yang W, et al,. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27 (47): 6550-6557.
3. Tong MJ, Pan CQ, Hann HW, et al,. The Management of Chronic Hepatitis B in Asian Americans. Dig Dis Sci 2011; 56 (11): 3143-3162.
4. Fattovich G, Bortolotti F, Donato F,. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 (2): 335-352.
5. Chen CJ, Yang HI,. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26 (4): 628-638.
6. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL,. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28 (9): 1067-1077.
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352 (26): 2673-2681. (Pubitemid 41007822)
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131 (6): 1743-1751. (Pubitemid 44958517)
9. Lai CL, Gane E, Liaw YF, et al,. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357 (25): 2576-2588. (Pubitemid 350294224)
10. Leung NW, Lai CL, Chang TT, et al,. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33 (6): 1527-1532. (Pubitemid 32496991)
11. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15): 1521-1531.
12. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57 (1): 167-185.
13. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6 (3): 531-561.
14. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662.
15. Chang TT, Gish RG, de Man R, et al,. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354 (10): 1001-1010. (Pubitemid 43357804)
16. Gish RG, Lok AS, Chang TT, et al,. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133 (5): 1437-1444. (Pubitemid 350029745)
17. Gish RG, Chang TT, Lai CL, et al,. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17 (1): 16-22.
18. Lai CL, Shouval D, Lok AS, et al,. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354 (10): 1011-1020. (Pubitemid 43357805)
19. Sherman M, Yurdaydin C, Sollano J, et al,. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130 (7): 2039-2049. (Pubitemid 43816960)
20. Sherman M, Yurdaydin C, Simsek H, et al,. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48 (1): 99-108. (Pubitemid 351975535)
21. Manns MP, Akarca US, Chang TT, et al,. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012; 11 (3): 361-368.
22. Yao G, Chen C, Lu W, et al,. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007; 1 (3): 365-372.
23. Yao G, Zhou X, Xu D, et al,. Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int 2007; 1 (3): 373-381.
24. Leung N, Peng CY, Hann HW, et al,. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49 (1): 72-79.
25. Liaw YF, Raptopoulou-Gigi M, Cheinquer H,. Kumar Sarin S, Tanwandee T, Leung N, Myers RP, Brown Jr RS, Shiffman M, Bialkowska J, Tang S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2011; 54 (1): 91-100.
26. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL,. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106 (7): 1264-1271.
27. Seto WK, Lai CL, Fung J, Yuen JC, Wong DK, Yuen MF,. Outcome of 4-year treatment of entecavir for treatment-naïve chronic hepatitis B. J Hepatol 2011; 54: S301.
28. Reijnders JG, Deterding K, Petersen J, et al,. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52 (4): 493-500.
29. Lampertico P, Vignao M, Facchetti F, et al,. Entecavir for nuc-naive chronic hepatitis B patients from clinical practice: long-term effects from a large multicenter cohort study in 376 patients. Hepatology 2009; 50 (Suppl 4): 408A.
30. Baqai SF, Yi DH, Gish RG,. Profound virologic response in chronic hepatitis B (CHB) patients treated with entecavir (ETV) in HBeAg positive and negative disease. Hepatology 2009; 50 (suppl 4): 530A (abstract 476).
31. Qi X, Xiong S, Yang H, Miller M, Delaney WE,. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12 (3): 355-362. (Pubitemid 46787980)
32. Villet S, Pichoud C, Billioud G, et al,. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48 (5): 747-755.
33. Nguyen MH, Trinh HN, Garcia RT, et al,. Treatment outcomes in patients with chronic hepatitis B (CHB) and partial response to adefovir (ADV) who wre switched to entecavir (ETV). Hepatology 2008; 48 (Suppl 1): 711A -Abstract 904.
34. Tenney DJ, Levine SM, Rose RE, et al,. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48 (9): 3498-3507. (Pubitemid 39129351)
35. Lange CM, Bojunga J, Hofmann WP, et al,. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50 (6): 2001-2006.
36. Lin CL, Kao JH,. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 123-130.